Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28639339 | 0.89 | LMNA (0.50) | LMNATHRB | |
| Ether SCHEMBL9720166 | 0.89 | LMNA (0.50) | LMNATHRB | |
| SCHEMBL7738082 | 0.87 | — | — | |
| SCHEMBL3318330 | 0.85 | — | — | |
| SCHEMBL3414553 | 0.85 | — | — | |
| SCHEMBL13409663 | 0.85 | — | — | |
| SCHEMBL31633561 | 0.82 | LMNA (0.50) | LMNATHRB | |
| SCHEMBL2220557 | 0.80 | TDP1 (0.45) | LMNATHRB | |
| SCHEMBL18775406 | 0.80 | LMNA (0.41) | LMNATHRB | |
| SCHEMBL8760073 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230246239-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2023-08-03 | — | — | US | claimed |
| EP-4213268-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2023-07-19 | — | — | EP | claimed |
| CN-116195088-A | Lithium secondary battery | 特拉沃特科技株式会社 | 2023-05-30 | — | — | CN | claimed |
| WO-2022054338-A1 | LITHIUM SECONDARY BATTERY | ＴｅｒａＷａｔｔ Ｔｅｃｈｎｏｌｏｇｙ株式会社 | 2022-03-17 | — | — | WO | claimed |
| WO-2025057311-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY | ＴｅｒａＷａｔｔ Ｔｅｃｈｎｏｌｏｇｙ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| WO-2025057310-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY | ＴｅｒａＷａｔｔ Ｔｅｃｈｎｏｌｏｇｙ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| WO-2025057309-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY | ＴｅｒａＷａｔｔ Ｔｅｃｈｎｏｌｏｇｙ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| US-20250007001-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240421354-A1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-20240250306-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2024-07-25 | — | — | US | disclosed |
| US-20240120549-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023170799-A1 | LITHIUM SECONDARY BATTERY | ＴｅｒａＷａｔｔ Ｔｅｃｈｎｏｌｏｇｙ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2021068866-A1 | HETEROCYCLIC COMPOUNDS AS STING MODULATORS | BEIGENE, LTD. (KY) | 2021-04-15 | — | — | WO | disclosed |
| US-10918624-B2 | Anti-cancer azole compounds | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-02-16 | — | — | US | disclosed |
| EP-0924789-B1 | Nonaqueous battery | SHARP KK (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20010053333-A1 | Antimicrobial flash-dry disinfectant aerosol | TRIOSYN CORP. | 2001-12-20 | — | — | US | disclosed |
| US-6132906-A | Nonaqueous battery | SHARP KABUSHIKI KAISHA (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0924789-A1 | Nonaqueous battery | Sharp Kabushiki Kaisha (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5104503-A | Radiation in presence of group 2b metal | YALE UNIVERSITY (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0153640-A2 | Process for the preparation of 1,2,3,4,5,6,7,8-octahydro-anthrahydroquinones | BAYER AG (DE) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918624-B2 | Anti-cancer azole compounds | RB1, API5, TP53 | LMNA 2763/4885THRB 4605/4885OPRM1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.